5.9 C
New York
Friday, March 29, 2024

Depomed Prevails Against Actavis In Gralise Case

Courtesy of Benzinga.

Related DEPO
Dow Flirts With 19,000, S&P 500 Approaches 2,000 & NASDAQ Trading At 14-Year Highs
Top 4 Small-Cap Stocks In The Drug Manufacturers-Other Industry With The Highest EPS Estimates

Shares of Depomed (NASDAQ: DEPO) are trading sharply higher following news of a favorable court ruling versus competitor Actavis (NYSE: ACT).

The docket from the case showed a judge ruled in favor “on all claims and counterclaims pending in this litigation.” The effective date of any FDA “approval with respect to Actavis’s ANDA that is the subject of this lawsuit shall be no earlier than the last expiration date of the 280, 962, 927, 989, 756, 332 and 992 Patents.”

A mid-day release from Depomed has since confirmed what the docket showed.

The news propelled the stock, which had been trading lower before the news hit, to rise nearly 16 percent to $15.11, before settling back down to $14.72, still up 11.8 percent on the day.

Posted-In: News Legal Movers

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments

Stay Connected

157,450FansLike
396,312FollowersFollow
2,280SubscribersSubscribe

Latest Articles

0
Would love your thoughts, please comment.x
()
x